Document:

<PAGE>
                                                                    Exhibit 10.8

          PATENT AND KNOW-HOW LICENSE AGREEMENT

          Made and entered into on February 18, 2003, by and between

          OMRIX BIOPHARMACEUTICALS LTD.

          MDA Building,
          Tel-Hashomer
          Israel
          (hereinafter - "OMRIX")

                                                                 on the one part

                                       AND

          AMERSHAM BIOSCIENCES AB

          Bjorkgatan 30
          751 84 Uppsala, Sweden
          (hereinafter - "AMERSHAM")

                                                               on the other hand

WHEREAS OMRIX possesses certain proprietary know-how, as to the technology and
methodology required to manufacture Plasminogen Removal Gel-TA Resin (as more
fully defined below as "PLASMINOGEN RESIN"): and

WHEREAS AMERSHAM has conducted certain development work in collaboration with
OMRIX relating to the Plasminogen Resin, without such work derogating in any way
from OMRIX's intellectual property rights with respect to the Plasminogen Resin
and/or the Patent(s): and

WHEREAS OMRIX and AMERSHAM wish to enter into agreements for the manufacture of
the Plasminogen Resin by AMERSHAM, and for the distribution and sale of the
Plasminogen Resin by AMERSHAM: and

WHEREAS AMERSHAM wishes to receive from OMRIX the Know-How and the License
necessary to manufacture the Plasminogen Resin in accordance with the Know-How
and to market and sell the Plasminogen Resin worldwide, and OMRIX is willing to
give AMERSHAM the Know-How AND grant AMERSHAM the License, subject to the terms
and conditions of this Agreement

NOW THEREFORE, in consideration of the covenants and obligations hereinafter set
forth, the parties hereto agree as follows:

      PORTIONS OF THIS EXHIBIT MARKED BY AN *** HAVE BEEN OMITTED PURSUANT
       TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE
                      SECURITIES AND EXCHANGE COMMISSION.

                                                                               1

<PAGE>

1.   DEFINITIONS

     In this Agreement, unless context otherwise requires, the following terms
     shall have the respective meanings assigned to them below:

     1.1. "AFFILIATES" shall mean any person, corporation, firm, partnership or
          other entity which directly or indirectly controls, owns, is owned by
          or is under common ownership with a party to this Agreement to the
          extent of at least fifty percent (50%) of the equity and having the
          power to vote on or direct the affairs of the entity.

     1.2. "AMERSHAM" shall mean AMERSHAM BIOSCIENCES AB, a Swedish corporation
          and including any entity controlling, owned or controlled by AMERSHAM.

     1.3. "CUSTOMERS" shall mean purchasers of Plasminogen Resin from AMERSHAM
          with the exclusion of OMRIX.

     1.4. "EFFECTIVE DATE" shall mean the date on which the last of the
          Agreements is executed.

     1.5. "IMPROVEMENTS" shall mean any additions, innovations or updates to the
          existing Know-How developed, reached or obtained by OMRIX or by
          AMERSHAM, which did not exist prior to the date of this Agreement and
          which update, simplify or in any way improve the Know-How so as to
          make it simpler, less costly or more efficient or so as to result in a
          superior Plasminogen Resin.

     1.6. "KNOW-HOW" shall mean and include all the information included in the
          Patent(s) and all know-how, knowledge, expertise, technology,
          methodology and technical information regarding Plasminogen Resin and
          any use thereof, including, without limitation, advice, guidance,
          directions, instructions and training, necessary to manufacture
          Plasminogen Resin, that is owned, possessed or controlled by OMRIX or
          licensed to OMRIX by a third party, and including Improvements.

     1.7. "NET SALES" shall mean, in the case of Plasminogen Resin that is sold,
          the cumulative invoice price of Plasminogen Resin in a form suitable
          for sale to the Customers (regardless of non-collectible accounts)
          less any (i) outbound transportation costs paid, (ii) insurance fees,
          (iii) bad debts, (iv) discounts, (v) allowed allowances and credits
          because of returns, or (vi) sales taxes. Such items not to be included
          in the Net Sales shall be considered to amount to four percent (4%) of
          the invoice price, unless AMERSHAM presents proof that the actual
          amount is higher.

     1.8. "OMRIX" shall mean OMRIX BIOPHARMACEUTICALS S.A., a company organized
          under the laws of Belgium and including its Affiliates.

     1.9. "PATENT(S)" shall mean patent application WO 02/095019designated as
          "Removal of Plasminogen From protein solutions" (and any patents
          granted in respect thereof) together with all foreign equivalents,
          divisionals, continuations, continuations-in-part, extensions,
          re-examinations and revisions (including any extensions thereof).

                                                                               2

<PAGE>

     1.10. "PLASMINOGEN RESIN" shall mean Plasminogen Removal Gel-TA Resin and
          such other products which, by utilizing the Know-How, can be
          developed, severally or collectively, as more fully described in the
          Patent Application.

2.   LICENSE

     2.1. Subject to the terms and conditions set forth in this Agreement, OMRIX
          hereby grants AMERSHAM and its Affiliates an exclusive, worldwide
          license under the Patents and the Know-how to manufacture, sell, have
          sold and market Plasminogen Resin (the "LICENSE"). OMRIX reserves a
          right to freely use the Plasminogen Resin in its own production
          processes and to grant non-exclusive licenses to Customers for the
          commercial use of Plasminogel Resin as described in Section 2.3.

     2.2. As long as AMERSHAM manufacture Plasminogen Resin it will sell OMRIX,
          at a fair market price and in accordance with Amersham standard supply
          conditions as regards lead times and delivery conditions (Conditions
          of Sale, as attached). Amersham undertakes to sell up to *** litre
          with *** days lead time. The parties intend to enter into a separate
          supply agreement when the annual volumes exceeds *** litres. In the
          event Amersham decides to stop manufacture the Plasminogen Resin it
          shall give OMRIX six (6) months written notice in advance. In the
          event that AMERSHAM stops supplying Plasminogen Resin for a period of
          over 5 months, OMRIX will have right to terminate this Agreement
          forthwith upon thirty (30) days written notice, provided AMERSHAM
          fails to supply the quantity of Plasminogen Resin ordered by Omrix
          within such notice period, and in addition to the provisions of
          Section 14 hereto, AMERSHAM will upon written request transfer to
          OMRIX all the know how specific to the manufacturing of the
          Plasminogen Resin, provided OMRIX agrees to reimburse AMERSHAM for its
          reasonable and verified costs in connection with such transfer (as
          opposed to consideration for the know how itself). AMERSHAM shall
          under no circumstances be obliged to disclose any secret manufacturing
          know-how relating to other products or AMERSHAMS general manufacturing
          methods.

     2.3. Without prejudice to the provisions of Sections 2.1-2.2 above,
          AMERSHAM undertakes to inform Customers that OMRIX owns the Patent and
          all other intellectual property rights related to the Plasminogen
          Resin, and that any Customer wishing to use Plasminogen Resin for any
          purpose falling under any valid claims of the Patent other then for
          research purposes, needs prior to such use, and as condition precedent
          thereto, to (a) contact OMRIX directly, (b) sign a license agreement
          with OMRIX (the "RESTRICTION NOTICE"). The Restriction Notice will be
          included by AMERSHAM in its product catalogue and on its website. In
          addition, an insert with the Restriction Notice shall be supplied with
          all packages of Plasminogen Resin. Notwithstanding the above, Amersham
          shall in no event be responsible for the Customer's use of the
          Plasminogen Resin, provided that AMERSHAM is not in breach of this
          Section 2.3. However, Amersham has no intention to act in breach of
          applicable patent law or any court orders prohibiting any supplies to
          a certain customer.

     2.4. Subject to Section 2.3, AMERSHAM shall not use the name of OMRIX nor
          of any of OMRIX's shareholders, directors, employees, agents, or
          Affiliates, nor the name of any inventor of Plasminogen Resin, nor any
          adaptation of

                                                                               3

<PAGE>

          such names, in any sales promotion, advertising, or any other form of
          publicity without the prior written approval of OMRIX in each case.

3.   APPLICATION AND OWNERSHIP OF PATENT(S)

     3.1. OMRIX shall be responsible and will bear all past, present and future
          costs relating to the Patent(s) and Patent(s) applications.

     3.2. The parties shall in good faith mutually decide in which countries to
          file Patent application(s) in the name of OMRIX, and obtain the best
          possible Patent protection.

     3.3  Should OMRIX decide not to file Patent(s) application in any certain
          country/ies), it shall promptly notify AMERSHAM of such decision. In
          such event, AMERSHAM, in addition to any other right it has, may take
          all necessary measures in order to obtain the best possible Patent
          protection in such country/ies and OMRIX undertakes to sign all
          documents necessary to effectuate such protection.

     3.4  AMERSHAM shall reimburse OMRIX for 50% of its fees and expenses
          relating to all agreed activities for the prosecution and maintenance
          of the Patents, provided however that AMERSHAM has been provided with
          a list of elected countries for the purpose of national phase and/or a
          draft of the filing so as to allow for review and approval at least
          thirty (30) days in advance. AMERSHAM's obligation to reimburse OMRIX
          shall not exceed 5 % of the Net Sales of the Plasminogen Resin per
          calendar year.

4.   DELIVERY OF KNOW-HOW

     Subject to applicable laws, rules, regulations and the provisions of this
     Agreement, and for the purpose of enabling AMERSHAM to more fully implement
     the License, OMRIX shall deliver to AMERSHAM all its documentary materials
     with respect to the Know-How, and provide AMERSHAM with reasonable
     assistance in the implementation of the Know-How in its plant in Uppsala.

     Nothing in this section shall require OMRIX to disclose to AMERSHAM, or
     grant AMERSHAM access to, any technological information received by OMRIX
     from a third party and subject to restrictions on use or disclosure.

5.   RESERVATION OF RIGHTS

     5.1. AMERSHAM agrees and acknowledges that the Know-How is the sole
          property of OMRIX, and nothing in this Agreement shall be construed as
          giving AMERSHAM any right or title to the Know-How, except for the
          License as specifically detailed in this Agreement.

     5.2. Except as described in Section 15.8 AMERSHAM shall not have the right
          to assign and/or to transfer and/or sublicense any of its rights and
          obligations under this Agreement to another or others without the
          prior written consent of OMRIX.

     5.3. Upon termination of this Agreement, all rights granted to AMERSHAM,
          under the License, shall revert back to OMRIX, and AMERSHAM shall have
          no further rights with respect to the rights ensuing from the License.
          However, upon expiration of the Patents or the Agreement (not as a
          result of

                                                                               4

<PAGE>

          early termination), AMERSHAM shall have a fully-paid up non-exclusive
          license to freely use the Know-how.

6.   OMRIX' WARRANTIES, REPRESENTATIONS AND DISCLAIMERS

     6.1. OMRIX represents and warrants that:

          6.1.1. that it has full authority to enter into this Agreement,

          6.1.2. that it has no knowledge of any third party rights that would
               affect its ability to grant the license hereunder,

          6.1.3. that to the best of its knowledge, all information and data to
               be provided to AMERSHAM is accurate and complete,

          6.1.4. that the Patents to the best of its knowledge are not infringed
               or attacked by any third party,

          6.1.5. that the Patents are not licensed to any third party, except as
               provided for in Section 2.1, and

          6.1.6. it is not aware of any third party patent rights that would be
               infringed by anything made, use or sold under the License.

     6.2. Save for the warranties set forth in Section 6.1 nothing In this
          Agreement shall be construed as:

          6.2.1. a warranty or representation by OMRIX as to the validity or
               scope of any right related to the Plasminogen Resin;

          6.2.2. a warranty or representation that anything made, used, sold or
               otherwise disposed of under the license granted in this Agreement
               will or will not infringe patents of third parties;

          6.2.3. an obligation to bring or prosecute actions or suits against
               third parties for infringement of OMRlX's intellectual property
               rights related to the Plasminogen Resin;

          6.2.4. an obligation to furnish any know-how or any services other
               than those specified in this Agreement.

     6.3. Except as otherwise expressly set forth in this Agreement, OMRIX makes
          no representation and extends no warranties of any kind, either
          express or implied, including but not limited to warranties of
          merchantability, fitness for a particular purpose, and validity of
          patent rights claims, issued or pending. OMRIX assumes no
          responsibilities whatsoever with respect to use, sale, or other
          disposition by AMERSHAM or its Customers or other transferees of
          products incorporating or made by use of the Know How.

7.   AMERSHAM'S WARRANTIES AND REPRESENTATIONS

     AMERSHAM represents and warrants that:

     7.1. AMERSHAM has the full authority to enter into and to perform all of
          the duties and obligations contemplated for AMERSHAM in this
          Agreement.

     7.2. The manufacture of Plasminogen Resin complies with all relevant laws,
          regulations, ordinances and rules.

                                                                               5

<PAGE>

8.   RUNNING ROYALTY

     As consideration for the right to use the Know How and the grant of the
     License, all as set forth in this Agreement, AMERSHAM undertakes to pay to
     OMRIX as earned royalties a royalty calculated as a percentage of Net Sales
     in accordance with the terms and conditions of this Agreement. The royalty
     is deemed earned as of the earlier of the date Plasminogen Resin is
     actually sold and paid for, the date an invoice is sent by AMERSHAM, or the
     date Plasminogen Resin is transferred to a third party. The royalty shall
     remain fixed while this Agreement is in effect at a rate of *** of the Net
     Sales in countries where the Patent is in force and *** percent in all
     other countries (hereinafter the "NET SALES ROYALTY"). Until any patent has
     been granted or if the application for the Patent is rejected, withdrawn or
     lapsed AMERSHAM shall pay a royalty of *** percent.

9.   ACCOUNTING FOR PAYMENTS

     9.1. The balance of any amounts which remain unpaid more than fourteen (14)
          days after they are due to OMRIX shall accrue interest until paid at
          the rate of one (1%) per month, However, in no event shall this
          interest provision be construed as a grant of permission for any
          payment delays.

     9.2. Except as otherwise directed, all amounts owing to OMRIX under this
          Agreement shall be paid in U.S. dollars to OMRIX at the address
          provided in the preamble to this Agreement.

     9.3. A full accounting showing how any amounts payable to OMRIX under
          Section 8 have been calculated shall be submitted to OMRIX on the date
          of each such payment. Such accounting shall be on a per-country basis.

10.  RECORD KEEPING AND REPORTS

     10.1. Earned royalties shall be reported and paid by AMERSHAM on behalf of
          itself and its Affiliates within sixty (60) days after each 1st March
          and 1st September based on the Net Sales generated by AMERSHAM and/or
          its Affiliates during the preceding six month period, Such payment
          shall be made to the account specified in writing by OMRIX. The
          payments due shall be accompanied by a statement showing the
          assessment of royalties and shall specify for each country the
          quantities and value of Products sold and the amount of returns and
          credits on those returns and the amount payable for the period.

     10.2. AMERSHAM shall keep books and records sufficient to verify the
          accuracy and completeness of AMERSHAM's accounting referred to above,
          including without limitation, inventory, purchase and invoice records,
          manufacturing records, sales analysis, general ledgers, financial
          statements, and tax returns relating to the Plasminogen Resin. Such
          books and records shall be preserved for a period not less than four
          years after they are created, both during and after the term of this
          Agreement.

     10.3. AMERSHAM shall take all steps necessary so that OMRIX may within
          fourteen (14) days of its written request, audit, review and/or copy
          all of the

                                                                               6

<PAGE>

          books and records to verify the accuracy of AMERSHAM's royalty
          reports during the last 36 months, however not more than once per
          year. Such review may be performed by a firm of independent public
          accountants designated by OMRIX, upon reasonable notice and during
          regular business hours. If a deficiency with regard to any payment
          hereunder is determined, AMERSHAM shall pay the deficiency within
          thirty (30) days of receiving notice thereof along with applicable
          interest as described in Section 9.1. If a royalty payment deficiency
          for a calendar year exceeds five percent (5%) of the royalties paid
          for that year, then AMERSHAM shall be responsible for paying OMRIX's
          out-of-pocket expenses incurred with respect to such review.

     10.4. At any time during the term of this agreement, OMRIX may, but not
          more than once per year, request in writing that AMERSHAM verify the
          calculation of any past payments during the last 36 months owed to
          OMRIX through the means of a self-audit. Within forty-five (45) days
          of the request, AMERSHAM shall complete a self-audit of its books and
          records to verify the accuracy and completeness of the payments owed.
          Within fourteen (14) days of the completion of the self-audit,
          AMERSHAM shall submit to OMRIX a report detailing the findings of the
          self-audit and the manner in which it was conducted in order to verify
          the accuracy and completeness of the payments owed. If AMERSHAM has
          determined through its self-audit that there is any payment
          deficiency, AMERSHAM shall pay OMRIX the deficiency along with
          applicable interest under Section 9.1 with the submission of the
          self-audit report to OMRIX.

     10.5. If OMRIX determines through its review under Section 10.2 or if
          AMERSHAM determines under its self-audit under Section 10.3 that there
          has been an overpayment to OMRIX, OMRIX will credit the overpayment
          within thirty (30) days of receiving notice thereof.

11.  CONFIDENTIALITY

     11.1. AMERSHAM undertakes to keep as strictly confidential all the data and
          information disclosed by OMRIX which has already and which will come
          to its knowledge under, pursuant or by reason of this Agreement
          including, without limitation, the Patent(s), Know-How and any part
          thereof, all data and information pertaining to the design,
          establishment and equipment of OMRIX, and to the manufacture processes
          of Plasminogen Resin and the sale and marketing thereof which is
          marked as "confidential" or if disclosed orally, which is confirmed in
          writing as being confidential within 30 days from disclosure,
          (hereinafter collectively - "CONFIDENTIAL INFORMATION"), and not to
          disclose Confidential Information to another or others nor to permit
          the use or utilization thereof by another or others. OMRIX undertakes
          to keep strictly confidential all the data and information disclosed
          by AMERSHAM which will come to the knowledge of OMRIX or by reason of
          this Agreement which is marked as "confidential'" or if disclosed
          orally, which is confirmed in writing as being confidential within 30
          days from disclosure (also referred to as "CONFIDENTIAL INFORMATION").

     11.2. Each party further undertakes that it shall not directly or
          indirectly use or utilize the other party's Confidential Information
          or any part thereof except for any purposes specified in this
          Agreement.

                                                                               7

<PAGE>

     11.3. Each party undertakes to cause each of its employees and consultants
          having contact with the Confidential Information to accept a
          confidentiality undertaking containing substantially the same
          confidentiality obligations contained in paragraphs 11.1 and 11.2
          above, and shall be responsible to the other party for any breach of
          such confidentiality obligations by any of its employees and
          consultants.

     11.4. The confidentiality obligations shall not apply to any part of the
          Confidential Information which

          11.4.1. at the time of disclosure or subsequently is published or
               otherwise generally available to the public other than through
               any act or omission on the part of the recipient party; or

          11.4.2. was in the possession of the recipient party at the time of
               disclosure; or

          11.4.3. was acquired from a third party who has the lawful right to
               make such disclosure; or

          11.4.4. is independently developed by the recipient party without
               reference to or use of the materials comprising the Confidential
               Information disclosed under this Agreement; or

          11.4.5. is required to be disclosed by the recipient party pursuant to
               a legally enforceable order, direction or other regulation but
               any such disclosure shall be only so far as necessary to give
               effect thereto.

     11.5. Upon termination or cancellation of the License for any reason
          whatsoever, all the Confidential Information of one party in the
          possession of the other party, its employees and consultants,
          including any copy thereof, shall be returned to the other party
          immediately, save for one copy for record purposes.

     11.6. The confidentiality obligations of AMERSHAM and its employees and
          consultants hereunder shall survive the termination of this Agreement
          for any reason whatsoever with five (5) years.

12.  INFRINGEMENT, LIABILITY AND INSURANCE

          In the event AMERSHAM is notified, advised or becomes aware of any
          infringement of the rights of OMRIX in and to the Know-How, it shall
          forthwith notify OMRIX thereof. Each of AMERSHAM and OMRIX shall, have
          the right, at its sole discretion, to take all necessary measures to
          protect and defend the rights of OMRIX against any such infringement,
          including without limitation, the filing of claims, and shall bear all
          relates costs, but shall consult with the other party before any
          actions are taken or any settlements are made. Notwithstanding the
          above, OMRIX shall have the exclusive right (but not obligation) to
          take, at its sole discretion, all necessary measures with respect to
          infringement which is not related to the manufacture of Plasminogen
          Resin. In such a case, OMRIX will be solely entitled to any damages
          won in such infringement claim. In any other infringement claim, the
          damages won will be evenly distributed between the parties, after
          deducting all reasonable costs born by the parties with respect to
          such infringement claim, unless one of the parties did not provide
          active assistance to the party who initiated the infringement
          protection

                                                                               8

<PAGE>

          proceedings, where in such a case the party handling the infringement
          claim will be entitled solely to any damages won in any such
          infringement claim.

     12.1. AMERSHAM shall be liable for, and undertakes to indemnify, defend and
          hold OMRIX, its affiliates, successors and assigns, and its officers,
          directors, agents, employees and shareholders harmless from any loss,
          liability, expense, cost, obligation, damage or claim (including
          reasonable attorney's fees) arising out of or resulting from (i) the
          material breach by AMERSHAM of any representation, warranty or
          covenant made by it in this Agreement and (ii) claims (including, but
          not limited to, third party suits and health authority or other
          regulatory proceedings) related to any negligent acts or omissions of
          AMERSHAM (iii) any defects in Plasminogen Resin manufactured by
          AMERSHAM (however any claims relating to supplies to OMRIX will be
          governed by AMERSHAM's Conditions of Sale).

     12.2. OMRIX shall be liable for, and undertakes to indemnify, defend and
          hold AMERSHAM, its affiliates, successors and assigns, and its
          officers, directors, agents, employees and shareholders harmless from
          any loss, liability, expense, cost, obligation, damage or claim
          (including reasonable attorney's fees) arising out of or resulting
          from (i) the material breach by OMRIX of any representation, warranty
          or covenant made by it in this Agreement and (ii) claims (including,
          but not limited to, third party suits) for infringement of the claims
          of the Patent(s).

     12.3. The right to indemnification, as provided in section 12.2 and 12.3 is
          conditioned upon the indemnified party promptly notifying the
          indemnifying party thereof in writing, and allowing indemnifying party
          and its insurers the opportunity to assume direction and control of
          the defense against such claims, at its sole expenses, including
          without limitation, the settlement thereof at the sole option of
          indemnifying party or its insurers to the extent that the indemnified
          party ' liability is not hereby invoked. The indemnified party will
          cooperate with indemnifying party and its insurer in the disposition
          of any such matter and the indemnified party will have the right to
          participate in the defence of any claim to which this section applies.

     12.4. AMERSHAM will maintain during the term of this Agreement liability
          insurance coverage appropriate to the risk involved in producing,
          manufacturing, selling, marketing, consuming, or advertising the
          Plasminogen Resin. Upon ninety (90) days after written request
          AMERSHAM will present evidence to OMRIX that the coverage is being
          maintained. In addition, AMERSHAM shall provide OMRIX with at least
          thirty (30) days prior written notice of any change in or cancellation
          of the insurance coverage.

     12.5. NONE OF THE PARTIES SHALL IN ANY EVENT BE LIABLE FOR ANY INDIRECT,
          CONSEQUENTIAL OR PUNITATIVE DAMAGE OF ANY KIND FROM ANY CAUSE IN
          RELATION TO THIS AGREEMENT, INCLUDING WITHOUT LIMITATION, LOSS OF
          PROFITS, OR GOODWILL OR BUSINESS INTERRUPTION.

13.  FORCE MAJEURE

     Either party shall be excused from any delay or failure in performance
     hereunder caused by any war, hostilities, general military mobilization,
     labour dispute, governmental requirement, act of God, earthquake, and any
     other causes beyond

                                                                               9

<PAGE>

     its reasonable control. If such delay in performance due to such cause
     shall continue for more than six (6) months the other party may terminate
     this agreement upon written notice to the delayed party.

14.  TERM AND TERMINATION

     14.1. This Agreement shall be effective as of the Effective Date until the
          expiration of the Patent. If no patent is granted this Agreement shall
          expire upon the fifth anniversary of the Effective Date.

     14.2. If for any reason whatsoever, AMERSHAM commits a breach of any of its
          material obligations, and such breach continues uncured for more than
          sixty (60) days after written notice demanding to cure the breach has
          been given to AMERSHAM or such breach cannot be cured. OMRIX shall,
          without prejudice to any other rights or remedy it may have in law or
          equity have the right to cancel the License, whereupon AMERSHAM shall
          not have the right to manufacture and/or market and sell Plasminogen
          Resins and/or utilize the Know-How or any part thereof in any manner
          whatsoever.

     14.3. Without prejudice to any other right of Omrix, OMRIX may immediately
          terminate this agreement upon the occurrence of the third separate
          payment default of at least thirty (30) days by AMERSHAM within any
          consecutive three year period, provided OMRIX has requested payment in
          writing for each default

     14.4. This Agreement may be terminated by either party:

          14.4.1. at any time by giving at least sixty (60) days written notice
               of such termination to the other party if AMERSHAM decides to
               and/or stops manufacturing Plasminogen Resin (except for any
               temporary stop, which do not affect AMERSAM's capability to
               deliver the Plasminogen Resin to OMRIX),

          14.4.2 if a bankruptcy petition or an application for the appointment
               of a trustee, administrator or a receiver is filed against the
               other party and is not dismissed or revoked within sixty (60)
               days.

     14.5. Upon the termination of this Agreement for any reason, nothing herein
          shall be construed to release either party from any obligation that
          matured prior to the effective date of such termination or from any
          obligation that by its nature survives termination. AMERSHAM shall
          remain obligated to provide an accounting for and to pay royalties
          earned to the date of termination. AMERSHAM may, however, after the
          effective date of such termination, sell all Plasminogen Resin, and
          complete Plasminogen Resin in the process of manufacture at the time
          of such termination and sell the same, provided that AMERSHAM shall
          remain obligated to provide an accounting for and to pay running
          royalties thereon.

15.  MISCELLANEOUS

     15.1. The parties acknowledge that, unless otherwise agreed in writing,
          AMERSHAM is acting as an independent contractor and is not acting as a
          partner, co-venturer or in any other joint capacity with OMRIX.

     15.2. AMERSHAM shall not encumber or otherwise grant a security interest in
          any of the rights granted hereunder to any third party.

                                                                              10

<PAGE>

     15.3. The provisions herein contained set forth the entire Agreement of the
          parties with respect to the subject matter thereof, supersede all
          previous communications, representations or agreements, whether oral
          or written, with respect to the subject matter thereof and no addition
          to or modification of this Agreement shall be binding upon either
          party unless reduced to writing and duly executed by the parties
          hereto in the same manner as the execution of the Agreement.

     15.4. The waiver by either party of any breach or alleged breach of any
          provision hereunder shall not be construed to be a waiver of any
          concurrent, prior or succeeding breach of said provision or of any
          other provision herein.

     15.5. This Agreement shall be governed by and construed in accordance with
          the laws of the English without regard to the choice of law principles
          that might otherwise be applied in such jurisdiction. The Parties
          expressly waive the application of the United Nation Convention of
          April 11, 1980 on the International Sale of Goods as amended from time
          to time. All disputes arising in connection with the Agreement shall
          be finally and solely settled in London under the Rules of
          Conciliation and Arbitration of the International Chamber of Commerce
          by one or three arbitrators appointed in accordance with the said
          Rules. The arbitration proceedings shall be conducted in the English
          language. Documents may be presented in other language if accompanied
          by an English translation. The procedural law of this place shall
          apply where the Rules are silent. The arbitral award shall be
          substantiated in writing. Any award rendered by the arbitrator(s)
          shall be payable within sixty (60) days of the rendition thereof.

     15.6. OMRIX and AMERSHAM hereby warrant and represent that the persons
          signing this Agreement have authority to execute this Agreement on
          behalf of the party for whom they have signed.

     15.7. All notices and other communications required or permitted to be
          given or sent hereunder shall be in writing and shall be sent by
          registered mail or by fax with confirmation sent by registered mail or
          delivered in person to the respective addresses of the parties as
          first herein above written or as may be advised by any of the parties
          in writing in due course.

     15.8. None of the Parties may transfer or assign any rights or obligations
          under this Agreement, however AMERSHAM shall have the right to
          transfer or assign its rights and obligations to an affiliated company
          and to a third party acquiror of all or substantially all of the
          assets of the business to which this Agreement pertains, provided that
          such third party is not a competitor of OMRIX and further provided
          that OMRIX' rights hereunder shall be preserved and shall not be
          harmed in any way.

IN WITNESS WHEREOF SIGNED by the parties hereto as of the day and year first
above written.

/s/ Mr. Nissim Mashiach                 /s/ Authorized Officer
-------------------------------------   ----------------------------------------
OMRIX BIOPHARMACEUTICALS LTD.           AMERSHAM BIOSCIENCES AB
By: Mr. Nissim Mashiach                 By: Authorized Officer
Title: General Manager                  Title: VP Bioprocess Separations

                                                                              11<PAGE>

                                                                    EXHIBIT 10.9

                                SUPPLY AGREEMENT
             ENTERED INTO AND SIGNED ON THIS 25 DAY OF MARCH, 2004

BY AND BETWEEN:  OMRIX BIOPHARMACEUTICALS LTD,
                 whose address for the purposes hereof is:
                 MDA Blood center
                 Tel Hashomer Hospital
                 Kiryat Ono, Israel

                 (Hereinafter referred to as: "OMRIX")

                                                              OF THE FIRST PART;

                                      AND

                 PLASTMED LTD.
                 a company registered in the______________________________,
                 whose address for the purposes hereof is
                 at____________________________________________________

                 (Hereinafter referred to as: "PLASTMED")

                                                             OF THE SECOND PART;

WHEREAS:    Omrix wishes to contract PlastMed for the manufacture and supply
            exclusively for and to Omrix of Quixil applicator devices, as denned
            and described in ANNEX A' to this Agreement (hereinafter: "THE
            DEVICES"); and

WHEREAS:    PlastMed has agreed to exclusively manufacture by sub-contracting
            the Devices for Omrix and supply the Devices exclusively to Omrix,
            according to the quantities, the timetables and the quality
            indicated in this Agreement: and

WHEREAS:    The parties wish to set in writing their mutual rights and
            obligations and all according to this Agreement;

NOW THEREFORE IT IS AGREED DECLARED AND STIPULATED BETWEEN THE PARTIES AS
FOLLOWS:

      PORTIONS OF THIS EXHIBIT MARKED BY AN *** HAVE BEEN OMITTED PURSUANT
       TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE
                      SECURITIES AND EXCHANGE COMMISSION.
<PAGE>

                                       2

1.    PREAMBLE AND APPENDICES:

            The Preamble to this Agreement and its appendices constitute an
            integral part hereof and shall be read jointly herewith.

2.    INTERPRETATION:

      2.1   This Agreement shall be governed by the law of Israel and it's
            sections shall be interpreted by it.

      2.2   The headings of the sections of this Agreement are intended for
            convenience only and shall not be used to interpret the sections of
            the Agreement and/or shall not affect the content thereof.

      2.3   In this Agreement the terms set forth below will have the meanings
            set out beside them unless the context shall require otherwise:

          "THE AGREEMENT"                        This Contract;

          "THE PARTIES" "A PARTY"                Omrix and/or PlastMed.

          "THE DEVICE"

                                                   Quixil applicator
                                                   device, as defined in
                                                   Annex A attached herewith
                                                   to this Agreement.

3     PERIOD OF THE AGREEMENT:

      3.1   This Agreement is entered into for a period of Five (5) years,
            commencing on the date of signing of the Agreement (hereinafter:
            "THE TERM").

      3.2   It is agreed that the Term is determined in view of the Parties
            commitments and in light of their mutual representations herein.
<PAGE>

                                       3

      3.3   At the end of the Term, should Omrix desire to order the manufacture
            and supply from another supplier(s), it shall first offer PlastMed
            to supply the new order(s) for the Device, at such price and under
            such timetable, terms of payment and other terms as offered to Omrix
            by such other supplier in good faith, provided however that PlastMed
            has fulfilled all of its obligations herein, including without
            limitations, manufacture of the Devices in accordance with the
            specifications and quality requirements setforth herein. In the
            event PlastMed shall exercise the above right of first refusal, the
            applicable terms of this Agreement shall apply to the manufacture
            and supply of the new order by PlastMed Mutatis Mutandis.

      3.4   The parties hereby agree and undertake that in this case, if
            PlastMed shall accept this offer to continue and supply the Devices,
            then the Terms of this Agreement shall be renewed automatically for
            an additional period of 1 year.

4.    PLASTMED'S OBLIGATIONS:

          PlastMed hereby undertakes to:

      4.1   Manufacture the Devices, control the quality thereof and supply the
            Devices to Omrix in strict compliance with the requirements of the
            US FDA and the European Community Authorities and in accordance with
            the instructions of Omrix, the technical specifications and quality
            standards detailed in ANNEX A' attached hereto (collectively the
            "TECHNICAL SPECIFICATIONS").

      4.2   The Devices shall be manufactured by PlastMed or by reliable sub
            contractor(s) of PlastMed. For avoidance of doubt. PlastMed shall be
            solely and fully responsible for the quality of the Devices and for
            their timely delivery to Omrix.

      4.3   It is agreed that the prices stated in Section 5.5 to this
            Agreement, include all works involved and/or related to the
            manufacture and supply of the Devices, including without limitation,
            planning, production, supervision, assembly of the Devices' various
            components, and delivery to Omrix of the Devices, as agreed herein.
<PAGE>

                                        4

      4.4   It is stipulated that the prices for the device as set in this
            Agreement includes PlastMed's expenses due to stock management,
            warehouse services and printing/labeling (including without
            limitation, the box and 3 sizes of tray lids but exclude
            sterilization and additional requirements or development of similar
            products such as long catheter or any other additions to the Devices
            as detailed in ANNEX A'. At the request(s) of Omrix, PiastMed shall
            change the printing on the Device/s boxes and/or on the tray lids.
            PiastMed shall bear the costs of the first two changes. Any
            additional printing changes shall be charged as shall be agreed
            between the parties in advance.

      4.5   Without prejudice to anything herein and in addition thereto,
            PiastMed shall provide the services listed in ANNEX A.

      4.6   During the Term and for a period of 36 months thereafter, PiastMed
            shall not manufacture devices similar to the Devices for anybody
            other than Omrix.

5.    OMRIX'S OBLIGATIONS:

      5.1   Subject to the performance by PlastMed of all its obligations, Omrix
            will order from PiastMed, after a running period, which will end on
            December 31st, 2004, at least 80% of all of its requirements for the
            Devices during the Term. Omrix shall be entitled to order no more
            than 20% of all of its requirements for the Devices during the Term
            from their current supplier or from any other manufacturer. Subject
            to such limit of 20% PlastMed shall be the exclusive supplier to
            Omrix with regard to the Device.
<PAGE>

                                       5

      5.2   Omrix will finance the cost of the molds required for the
            manufacture of the Devices. The molds shall be designed and planed
            by PlastMed and ordered by PlastMed, from a reliable mold maker.
            PlastMed shall be solely and fully responsible for the quality of
            the molds and their suitability for their purpose.

          The molds will be ready no later than 7 months as of the signing date
          of this Agreement. The molds will be held by PlastMed or its
          subcontractors, as the case may be, in trust and on behalf of Omrix,
          provided however, that Omrix shall not be entitled to take physical
          possession of the molds until the payment by Omrix in full of the
          amount of *** EURO which shall be paid in the following manner: ***
          Euro in advance at the date of signing this Agreement. *** Euro shall
          be paid within 12 months thereafter, the remaining *** Euro shall be
          paid in 4 equal installments during the second year of this Agreement
          i.e. at: February 1st, at May 1st, at August 1st and at November 1st.
          The molds shall be deigned and planed for 1.000.000 guaranteed shots,
          all maintenance and repair costs after 1.000.000 shots shall be paid
          by Omrix up to *** from the original cost of the molds. PlastMed will
          be responsible to store, keep and maintain the molds up to 1 M shots.
          PlastMed will be responsible for storing and keeping the molds under
          good conditions and will assure that no damage theft etc will happened
          to the molds.

      5.3   Prices per one Device packed in printed box are DDP (Delivered all
            Duties Paid with the exception of VAT) Cure Medical Warehouse at
            Emek Hefer Industrial Area, Israel (INCOTERMS 2000), according to
            the quantities ordered and are as stated in the following chart.

          Quantity ordered: Price per Device in USD:

           Up to 60,000      ***
           Devices
           60,001-120,000    ***
           120,001-200,000   ***
           200,001 and more  ***

      5.4   Omrix shall pay during each calendar year an amount corresponding
            with the above chart, in accordance with the quantities forecasted.
            At the end of the year the parties will carry an adjustment in
            accordance with the actual quantities ordered, and an appropriate
            credit note or debit note shall be issued by PlastMed to Omrix. In
            the event that a debit note was issued, Omrix shall pay the amount
            specified therein within 21 working days of the receipt of such
            debit note.
<PAGE>
                                      6

      5.5       It is agreed that in addition to every payment aforementioned
                (which incorporates all duties that are the responsibility of
                PlastMed as per delivery terms DDP at Cure Medical's warehouse
                at Emek Hefer Industrial area. Israel INCOTERMS 2000). Omrix
                shall bear any additional tax, including but notwithstanding
                V.A.T., or any other tax the Israeli law shall require from
                Omrix.

            Such  taxes shall be added to any sum aforementioned, at the date
            of payment.

      5.6       In the event that PlastMed will fail to deliver the first order
                within 8.5 months from the date of signing this agreement (the
                "FIRST SUPPLY DATE"), Omrix shall be entitled to receive to it's
                possession, free of any liens, encumbrances and/or charges the
                mold/s that have been manufactures by sub-contractors for
                PlastMed, for the purpose of manufacturing the Device, provided
                that Omrix paid PlastMed the entire cost of the molds as
                detailed in Section 5.2., Such 8.5 month period shall be
                extended by Omrix, if it shall be apparent that the extension is
                not required due to PlastMed's gross negligence or malice.

      5.7       Omrix shall transfer the agreed upon payments by a Bank Transfer
                directly to PlastMed's Bank Account or to any other bank account
                as instructed in writing by PlastMed.

      5.8       In case PlastMed shall instruct Omrix to transfer any of the
                aforementioned payments to an Israeli bank account then any such
                transfer shall be made according to the exchange rate at the
                date of payment.

      5.9       Money transfer shall not be deemed accepted until such time as
                Omrix shall provide PlastMed with a suitable endorsement
                confirming the transfer.

6.    ORDERS AND DELIVERY:

      6.1   ANNUAL FORECAST

         6.1.1    Omrix shall deliver to PlastMed an annual purchasing forecast
                  for each calendar year (hereinafter: "THE ANNUAL FORECAST").

<PAGE>

                                      7

         6.1.2    The Annual Forecast for each year shall be delivered in
                  writing, no later than October 1st of the preceding calendar
                  year, and shall be updated as of April 1st of such calendar
                  year, as long as the Annual Forecast remains in the limits of
                  the Annual Commitment as defined in 6.1.3.

         6.1.3    Omrix shall be obliged to purchase in each and every
                  calendar year a quantity, which is not less than 75% and
                  not more than 125% of the Annual Forecast for such
                  calendar year (hereinafter: "THE ANNUAL COMMITMENT"). Any
                  difference between the amount actually purchased during a
                  calendar year and the Annual Forecast shall be purchased
                  during the following calendar year.

         6.1.4    PlastMed shall be prepared to supply Omrix all the quantity of
                  Devices detailed in the Annual Forecast, according to the
                  dates of delivery therein. Without prejudice to the above, in
                  the event Omrix shall order quantities of the Devices
                  exceeding 125% of the Annual Forecast, PlastMed will use its
                  best endeavors in order to supply the entire quantity ordered.

   6.2

         6.2.1    To the extent possible in view of existing orders placed with
                  Omrix and subject to section 6.2.2, Omrix shall place with
                  PlastMed quarterly orders not later then December 1st for the
                  quarter beginning January 1st of the next year), March 1st
                  (for the quarter beginning on April 1st.), June 1st (for the
                  quarter beginning on July 1st.) and September 1st (for the
                  quarter beginning on October 1st) of each calendar year
                  (hereinafter: an "Quarterly Order").

         6.2.2    Each Quarterly Order shall include purchase of not less than
                  25% of the Annual Commitment for Devices.

         6.2.3    Each Order shall include the required quantity of Devices, and
                  the exact intended date of delivery, which shall be at least
                  60 (sixty) working days following the date of the Order
                  (hereinafter: the "DELIVERY DATE").

         6.2.4    PlastMed shall confirm its acceptance of the Order in writing,
                  no later than 7 (seven) days of receipt of the Order."

<PAGE>

                                      8

         6.2.5    Payment terms shall be net + 30 days of the delivery date of
                  each consignment.

6.4       DELIVERY:

         6.4.1    PlastMed will supply the Devices to Omrix DDP (Delivered all
                  Duties Paid with the exception of VAT) Cure Medical Warehouse
                  at Cure Medical's warehouse, Israel (INCOTERMS 2000), at the
                  prices indicated in section 5.5 above. PlastMed warrants that
                  the Devices, which shall be purchased by Omrix from PlastMed,
                  shall be manufactured in accordance with the terms of this
                  Agreement and shall be free from any defects.

         6.4.2    After Omrix or it's representative collects the Devices in
                  accordance with the terms of section 6.4.1 above, the
                  responsibility, for the Devices shall fully transfer and lie
                  with Omrix.

         6.4.3    Following collection of the goods by Omrix, Omrix shall have a
                  twenty one working days period to file any claim with PlastMed
                  for any defective Device, unless Omrix will notify PlastMed
                  that the Devices are being held in inventory, in which case
                  the twenty one days shall only commence on the date when the
                  Devices would be delivered to Omrix's customer(s), but in any
                  event no later then 4 months from the date when the Devices
                  were delivered by PlastMed (hereinafter the "DEFECTIVE CLAIM
                  PERIOD").

                  After the expiry of said Defective Claim Period, Omrix shall
                  be deemed to have received the Devices at its full
                  satisfaction. Notwithstanding the above, PlastMed shall be
                  responsible for any defective Device(s), including if the
                  defect and/or incompatibility with the Technical
                  Specifications has been discovered after the Defective Claim
                  Period, provided that a reasonable check of the Device(s) by
                  Omrix during the Defective Claim Period did not reveal any
                  defect and/or incompatibility of the Device(s) and further
                  provided that Omrix informed PlastMed of the defective
                  Device(s) within 21 twenty one working days period of the
                  defect and/or incompatibility.

<PAGE>

                                      9

         6.4.4    PlastMed shall replace, at its sole cost and expense, any and
                  all defective Device(s) (provided such defect occurred prior
                  to delivery to Omrix) and/or Device(s) not complying with the
                  Technical Specification, provided that Omrix has notified
                  PlastMed thereof within the time limit set in section 6.4.3
                  above.

         6.4.5    If Omrix, for any reason, is unable to accept the Device(s)
                  at the time it is due and ready for delivery, PlastMed shall
                  store the Device(s) free of charge for an additional period of
                  six months, safeguard it and take all reasonable steps to
                  prevent its deterioration during this period.

         6.4.6    PlastMed acknowledges that it is aware of the fact that supply
                  of the Devices to Omrix in complete compliance with the
                  Technical Specifications and the delivery on times requested
                  by Omrix is crucial to the supply by Omrix of biological glue
                  to its customers, and material deviation there from by more
                  than 21 working days may cause Omrix irreparable damages.

7.  TRANSFER OF TITLE:

      Until delivery the Devices will be held by PlastMed in trust and on behalf
      of Omrix. The Title in the Devices shall pass to Omrix upon delivery,
      without derogating from PlastMed's right to be fully paid for the Devices
      in accordance with the terms of this Agreement.

8.  FDA, CE APPROVALS:

      Omrix will prepare all the applications for the approval of the
      manufacture of the Devices by the US and EC authorities. PlastMed shall
      extend to Omrix all reasonable assistance required for the preparation of
      such applications.

9.  LICENSES AND CUSTOM CLEARANCE:

      Subject to the provisions of Section 6.4.1 above, Omrix hereby undertakes
      to obtain the necessary Import / Export or any other Licenses (if
      required), and to make all the necessary arrangements including all
      payments due in order to obtain clearance for the purchase of the Device
      according to this Agreement.

<PAGE>

                                     10

10. FORCE MAJEURE:

      10.1           Force Majeure, under the present Agreement, denotes all
                     events which did not exist at the date of the signing of
                     this Agreement and/or which occur beyond the will and
                     control of the parties, and the occurrence and effects of
                     which cannot be prevented by measures and means which in
                     the specific situation may reasonably be required and owing
                     to which it is impossible to perform the Agreement within
                     the terms and on the conditions hereof.

      10.2      Both parties shall use all efforts to perform their respective
                obligations under this Agreement, but shall be excused for
                failure to perform or for delay in performance hereunder due to
                Force Majeure, including causes beyond the control of either,
                such as fires, strikes, floods, epidemics, war, riots.

      10.3      Throughout the period of Force Majeure the obligations of both
                parties are automatically extended for the duration of the delay
                caused by Force Majeure.

11. PLASTMED - AN INDEPENDENT CONTRACTOR:

    It is hereby agreed between the parties as follows:

      11.1      It is agreed and known to the parties that in order to produce
                and supply the Device, PlastMed is planning to manufacture the
                Device in a unique and exclusive manner.

                Therefore, it is agreed that PlastMed acts as an independent
                contractor in executing this Contract and/or in providing the
                Services under this Contract, and no right granted under the
                Contract to Omrix or any persons appointed by them or acting in
                their name or on their behalf, to supervise or intervene in any
                manner in the execution of PlastMed's work and/or in the
                provision of the Services, is to be regarded as anything more
                than a means to ensure the full performance of the provisions of
                the Contract, and PlastMed and its workers or any person
                employed by it in providing the Services will have no rights of
                employees of Omrix, and will not be entitled to any payment,
                compensation or other benefits from Omrix in connection with the
                performance of the Contract or any instruction given there
                under, or in connection with the rescission or termination of
                the Contract, for any reason whatsoever.
<PAGE>

                                       11

      11.2  That any person employed by Omrix connected to this contract will
            have no rights of employees of PlastMed, and will not be entitled to
            any payment, compensation or other benefits from PlastMed in
            connection with the performance of the Contract or any instruction
            given there under, or in connection with the rescission or
            termination of the Contract, for any reason whatsoever.

12.   Omrix Warrants and guarantees that the design, construction and quality of
      Device to be Supplied under this Agreement comply in all aspects and with
      all relevant requirements of Law, Statute, Statutory Rule or Order, or
      other instrument having the force of Law in the State which may be in
      force at the time when the same are supplied. In the event that no such
      Law, Statute or Order exist in a certain territory where the Device/s is
      supplied, Omrix takes all responsibility to such supply and shall
      indemnify and hold PlastMed harmless in the event of any damage, expenses
      or harm due to such supply.

13.   INFRINGEMENT OF PATENTS:

      13.1  Omrix hereby declares that it holds title by assignment to the
            invention known as "QUIXIL" applicator device that is the subject of
            Applicator device for applying a multiple fluid, in particular a
            multi-component tissue glue, Patents: USA: Application No.
            09/254552, Patent no. 6,113,571. Europe: Application no. 96 931
            070,5, Patent no. 0 925026.

      13.2  Subject only to the limitations on liabilities set out in this
            Section 13.2 and pursuant to the provisions of Section 13.3 Omrix
            hereby agrees to immediately indemnify PlastMed and hold it harmless
            from any expanses awards or recoveries finally assessed by a court
            of competent jurisdiction and specifically resulting from any
            infringement of any patent, registered design, trade mark or trade
            name protected in Israel or any other place by reason of
            manufacturing of the Devices, the use or sale by Omrix of the
            Devices manufactured by PlastMed, provided, however, that Omrix's
            duty to indemnify shall be subject to PlastMed's promptly notifying
            Omrix in writing of any notice PlastMed receives claiming or
            asserting infringement of a patent or registered design or trade
            mark or trade name, to which this indemnity applies, and lending all
            reasonable assistance, at its expense, in the defense or settlement
            of such suit which defense shall be under the control and direction
            of Omrix.
<PAGE>

                                       12

      13.3    Should Omrix decide to take control of the defense it shall
              notify PlastMed so, and in such case Omrix shall bear the expense,
              and shall have sole and complete control of the defense, conduct
              all negotiations for the settlement, adjustment or compromise of
              all aspects of any suit with respect to which Omrix shall have an
              obligation to indemnify PlastMed under Section 13.2 above. As long
              as PlastMed will take control of the defense, Omrix, subject to
              the fulfillment by PlastMed of its obligations under Section 13.2
              above, will bear the reasonable cost of PlastMed defense in such
              proceedings, provided the infringement is not a result of
              manufacture of the Device by PlastMed and/or any of its
              subcontractors not in accordance with the Technical Specifications
              and any other relevant terms of this Agreement.

      13.4  The parties warrants that they are the possessor of certain
            intellectual property rights, formulas, drawings, plans,
            specifications, software programs, algorithm, assembling, marketing
            and other business experiences, technical knowledge and Know-how in
            the field of design, manufacturing, assembling and marketing of the
            Device, that they consider to be confidential or proprietary
            information of value (hereinafter: "CONFIDENTIAL INFORMATION").

      13.5  Any design or instructions or act furnished or given by one party
            (the "Granting Party") to the other party (the "Receiving Party")
            shall not be deemed as giving the Receiving Party any consent to
            infringe any Confidential Information of the Granting Party and/or
            to grant the Receiving Party any right with respect thereto. For
            avoidance of doubt, nothing in this Agreement shall be construed as
            granting the Receiving Party any right or title to any part the
            Confidential Information and/or to any intellectual property of the
            Granting Parry, whether registered or not. Disclosure of
            Confidential Information by PlastMed to any sub-supplier shall be
            subject to the written prior approval of Omrix and to such sub-
            supplier signing a confidentiality agreement, which will include the
            provisions of Sections 13.4, 13.5 and 15 hereof, securing Omrix
            rights herein.

      13.6  Omrix, directly or indirectly (including, but not limited to other
            companies connected to Omrix whether by other agreements or by other
            businesses relations and/or companies Omrix holds their shares or
            companies that holds Omrix shares), shall not during the term of
            this Agreement and 4 (four years) thereafter order the supply or
            manufacture of the Device or any part thereof or any other product
            or device from any subcontractors or suppliers of PlastMed.

<PAGE>

                                       13

14.   BANKRUPTCY AND LIQUIDATION:

      14.1  If a party hereto ( a "BANKRUPT PARTY") shall at any time, becomes
            bankrupt, or shall have a receiving order or administration order
            made against it, or shall make any composition or arrangement with,
            or for the benefit of its creditors or shall purport to do so, or if
            it shall become insolvent or bankrupt, or any application shall be
            made under the Bankruptcy Act, for the time being in force, for
            sequestration of its assets, or a trust deed shall be granted by it
            on behalf of its creditors, or if the Bankrupt Party shall file a
            request to be wound up (not as result of reconstruction or
            amalgamation) or if a receiver, or manager on behalf of the creditor
            shall be appointed, or if circumstances shall arise which entitle
            the Court or a creditor to appoint a receiver or manager, or which
            entitle the Court to make a winding up order, then the other party
            hereto shall be at liberty:

    14.1.1  To cancel the Agreement by notice in writing without
                    compensation to the Bankrupt Party, or

    14.1.2  To give any such receiver or liquidator or other person the
                    option to carry out the Agreement.

      14.2  The exercise of any of the rights granted to a party under sub-
            Section 14.1 hereof should not prejudice or affect any other right
            of such party.

15.   SECRECY:

         The parties undertake that at all times hereafter, they shall keep
         confidential, and not disclose to any third party, any information
         concerning this Agreement, any knowledge or information concerning
         the other party and in connection with the performance of this
         Agreement, reaching it by virtue of or during the course or
         incidental to the performance of this Agreement or the provision of
         the Services, during, before the commencement of or after the
         termination of the Agreement Term. Without derogating from the
         above, PlastMed shall keep as strictly confidential all the
         information that will come to its knowledge and which refers to the
         Devices and/or to Omrix and/or to the business of Omrix, subject to
         terms of this Agreement.

16.   NOTICE OF LABOR DISPUTES:

<PAGE>

                                       14

        Whenever an actual or potential labor dispute threatens to delay the
        performance of this Agreement, the affected party shall immediately
        give notice thereof to the other party.

17.   INDEMNIFICATION:

      17.1  PlastMed shall defend, indemnify and hold harmless Omrix from any
            and all claims pertaining to any defects in the Devices to be
            supplied by PlastMed to Omrix, except for any defect/s stemming from
            the or pertaining to the Technical Specifications. It is further
            agreed that PlastMed shall not be responsible or liable to Omrix
            and/or any third party except for damages due to Devices that do not
            comply with the Technical Specifications

      17.2  Omrix shall be solely liable for any direct or indirect physical or
            any other damage or loss which any third party has suffered or might
            suffer due to any use of the Device and/or act and/or omission of
            Omrix or anyone acting on his behalf. It is stipulated that Omrix
            shall be liable for any personal injury to or death of any person
            arising out of or in the course of or caused by the performing of
            this Agreement including any such liability caused by use of the
            Devices, provided, however, that any such direct or indirect
            physical or any other damage or loss were not caused as result of
            poor workmanship and/or any defects in a Device supplied by PlastMed
            except for any defect/s stemming from the or pertaining to the
            Technical Specifications, but including any defects in a Device
            resulting from manufacture thereof not in accordance with the
            Technical Specifications. The above provisions shall apply to
            PlastMed only with regard to the supply and manufacture of Devices
            that do not comply with the Technical Specifications.

      17.3  According to the provisions of Section 17.2 above, Omrix or
            PlastMed, as the case may be, shall be liable for, and shall
            indemnify each other against any expense, liability, loss, claim or
            proceedings in respect of any injury or damage whatsoever to any
            person insofar as such injury or damage arises out of or in the
            course of or by reason of the carrying out of this Agreement and or
            use of the Device. The above provisions shall apply to PlastMed only
            with regard to the supply and manufacture of Devices that do not
            comply with the Technical Specifications.

<PAGE>

                                       15

      17.4        Omrix or PlastMed, as the case may be, shall further indemnify
                  each other against and hold it harmless from any and all
                  direct losses, damages and liabilities (or actions in respect
                  thereof), arising out of, resulting from, based on or
                  otherwise incurred by Omrix or PlastMed, as the case may be,
                  in connection with any misrepresentation, breach of a warranty
                  or failure to perform any covenant or obligation of Omrix or
                  PlastMed, as the case may be, under this Agreement, including
                  all exhibits, schedules and other documents relating hereto.
                  The above provisions shall apply to PlastMed only with regard
                  to the supply and manufacture of Devices that do not comply
                  with the Technical Specifications.

18.           LIABILITY & INSURANCE:

      18.1        Without derogating from any of PlastMed's obligations herein,
                  PlastMed shall be fully and solely liable and responsible for
                  every Device as of the date on which a Purchase Order is
                  issued to PlastMed by Omrix and until the Device is delivered
                  to Omrix in accordance with the terms of this Agreement and
                  thereafter, for the a period of 12 months from the Delivery
                  Date (hereinafter the "LIABILITY PERIOD"). The above
                  provisions shall apply to PlastMed only with regard to the
                  supply and manufacture of Devices that do not comply with the
                  Technical Specifications.

      18.2        Omrix shall be solely liable for any direct or indirect
                  physical or any other damage or loss which any third party has
                  suffered or might suffer due to any use of the Device, and/or
                  act and/or omission of Omrix or anyone acting on his behalf.
                  It is stipulated that Omrix shall be liable for any personal
                  injury to or death of any person arising out of or in the
                  course of or caused by the performing of this Agreement
                  including any such liability caused by use of the Devices,
                  provided, however, that any such direct or indirect physical
                  or any other damage or loss were not caused as result of poor
                  workmanship and/or any defects in a Device supplied by
                  PlastMed except for any defect/s stemming from the or
                  pertaining to the Technical Specifications, but including any
                  defects in a Device resulting from manufacture thereof not in
                  accordance with the Technical Specifications. The above
                  provisions shall apply to PlastMed only with regard to the
                  supply and manufacture of Devices that do not comply with the
                  Technical Specifications.
<PAGE>

                                       16

      18.3          Without derogating from the foregoing and from any of
                    PlastMed's and Omeric's obligations herein, The parties
                    shall indemnify and hold harmless each other for their
                    Liabilities and obligations as described above.

      18.4          It is expressly clarified that in no event PlastMed's
                    obligations under Section 18.3 shall be limited to the
                    extent of any insurance available to and or provided by
                    PlastMed and/or by Omrix.

      18.4A         For avoidance of any doubt, it is agreed that PlasMed
                    shall be liable according and with regard to this agreement
                    solely and only in the event that PlastMed manufactured a
                    defective Device, which does not comply with the Technical
                    Specifications.

      18.5        Without derogating from PlastMed's liabilities and/or
                  obligations pursuant to this Agreement or pursuant to any law.
                  including but without limitations, PlastMed's obligation to
                  insure itself with various insurances as it may think fit,
                  like damage, theft etc and without Omrix assuming any
                  liability vis-a-vis PlastMed the following provisions with
                  respect to Insurance shall apply:

                  18.5.1      Omrix shall provide and maintain while the
                              agreement is being performed and for 7 (seven)
                              years AFTER the actual use of the device,
                              insurance with the limit of the insurance pursuant
                              thereto being not less than 5,000,000 USD per
                              event and in total for the term, in respect of any
                              injury or damage which might be caused in
                              consequence of any defect in the Devices. "Product
                              Liability" insurance with the limit of the
                              insurance pursuant thereto being not less than
                              5,000,000 USD per event and in total for the term,
                              in respect of any injury or damage which might be
                              caused in consequence of any defect in the
                              Devices.
<PAGE>

                                       17

                  18.5.2      It is agreed that if Omrix's Product Liability
                              insurance is cancelled or the scope thereof is
                              narrowed, and/or if the Omrix does not provide
                              confirmation of the insurance required from him
                              according to this Agreement, any of them and/or
                              the renewal thereof in time, or if the
                              confirmation does not conform with the provisions
                              hereof, PlastMed may, but shall not be bound to,
                              take out the said insurances, or any of them, at
                              its expense, without such imposing any liability
                              on PlastMed and/or anyone on its behalf or
                              exempting Omrix from any liability imposed on it
                              pursuant hereto and/or at law. Omrix shall
                              indemnify PlastMed immediately upon its first
                              demand, for any amount paid by PlastMed as
                              insurance premiums for Omrix as aforesaid. The
                              amount of the indemnity shall be deemed a debt due
                              to PlastMed from Omrix, pursuant to the
                              Agreement's provisions.

                  18.5.3      The policies shall include:

                              (i) PlastMed its subsidiaries and its as an equal
                              insured;

                              (ii) a "Cross Liability" clause;

                              (iii) waiver, by the insurer, of any right of
                              subrogation against any of the those included in
                              the insured name including any of their employees.

                  18.5.4      PlastMed alone shall be liable for paying the
                              excess specified in the policy.

                  18.5.5      Insofar as in PlastMed's opinion or pursuant to
                              the terms of this Agreement and any annex thereto
                              there is a need to extend the scope of the
                              insurance or to take an additional insurance,
                              PlastMed undertakes to do so at its expense.

19.   ENTIRE AGREEMENT

            This Agreement, including the tender, all exhibits, schedules and
            other documents relating hereto, constitutes the sole, entire and
            binding agreement among the parties hereto pertaining to the
            transactions contemplated herein and embodies agreed upon terms
            binding upon the parties in respect thereof No party to this
            Agreement shall be liable or bound by prior or contemporaneous,
            express or implied representation, warranty. Statements, promise,
            covenant or agreement pertaining to said transactions made by it or
            on its behalf unless same is expressly or impliedly set forth or
            referred to herein.
<PAGE>

                                       18

20.   AMENDMENTS, WAIVERS, DISCHARGE AND CONSENT:

      20.1        No failure to exercise and no delay in exercising any right,
                  remedy, privilege or power under or pursuant to this Agreement
                  shall operate as a waiver thereof, nor shall any single or
                  partial exercise of any such right, remedy, privilege or power
                  preclude any other or further exercise thereof or the
                  exercise of any other right, remedy, privilege or power.

      20.2        No amendments change or modification of this Agreement or any
                  of the provisions, term or conditions hereof, on waiver of a
                  right, remedy, privilege or power, or discharge of an
                  obligation or liability, conferred upon, vested in or imposed
                  on either party under or pursuant to this Agreement, and no
                  consent to any act or omission pertaining hereto shall come
                  into operation and be effective unless duly embodied in a
                  written instrument signed by or on behalf of the party against
                  whom such amendment, change, modification, waiver, discharge
                  or consent is asserted or sought.

21.   PARTIAL INVALIDITY OR UNENFORCEABILITY:

            If any provision of this Agreement is held to be invalid or
            unenforceable, such invalidity or unenforceability shall not
            invalidate this Agreement as a whole, but this Agreement shall be
            construed, as though it did not contain the particular provision
            held to be invalid or unenforceable and the rights and obligations
            of the parties shall be construed and enforced only to such extent
            as shall be permitted by law.

22.   ORDER OF PRECEDENCE:

            The following order of precedence shall govern in the event of a
            conflict between documents of this Agreement:

      1.    The Technica Specifications of Omrix.

      2.    This Agreement

      3.    Proposal Documents.

            Appendices to the Proposal Document.

            Omrix Product liability insurance.

<PAGE>

                                       19

23.   LAW & ARBITRATION

            All disputes between the Parties hereto which cannot be amicably
            settled between such Parties, shall be finally settled solely by
            arbitration of a single arbitrator, selected and appointed by mutual
            agreement between the Parties in dispute. Should the Parties in
            dispute not reach agreement concerning the appointment of the
            arbitrator, within fourteen (14) days after delivery by one of those
            Parties to the other Party/is of a written notice requesting that
            the dispute be referred to arbitration, and then the arbitrator
            shall be selected by the Chairman of the Israel Law Bar.

      The arbitration proceedings shall be conducted according to the Rules of
      Arbitration of the Law of Israel, and shall be held in Tel- Aviv

24.   NOTICES:

      24.1        Any notices submitted to the above mentioned official address
                  of the parties, will be deemed received by that party after 7
                  days from date of submission to a Post Office by registered
                  Air-Mail, or in case of Fax - 24 hours dispatch, subject to
                  receipt of fax confirmation.

      24.2        All the above-mentioned time terms refer to ordinary working
                  days and are subject to the existence of normal communication
                  conditions.

      IN WITNESS WHEREOF THE PARTIES HERETO HAVE SIGNED THIS AGREEMENT:

      /s/ Authorized officer                       /s/ Nissim Mashiach
      ----------------------------                 ----------------------------
             PLASTMED                                        OMRIX

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00096-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00096-of-00352.parquet"}]]